Roadmaps determine Gavi’s long-term market ambition for each vaccine or immunisation product. They present both a short- and long-term view of how we would like the market to evolve for a particular vaccine or product, and identify mechanisms that can help to influence it.

Gavi has been engaged in cholera vaccination since 2014 through the funding and support of the global stockpile of cholera vaccines. This document is the public summary of the supply and procurement roadmap for cholera vaccines.

In 2014, Gavi has committed to purchase Ebola vaccine for a global stockpile as soon as a safe, effective vaccine is recommended for use by the World Health Organization. This document is the public summary of the supply and procurement roadmap for Ebola vaccine.

Gavi established the Cold Chain Equipment Optimisation Platform (CCEOP) in June 2015 as a strategic and targeted approach to address the challenges of improving the vaccine cold chain with higher-performing equipment. This document provides a summary of the supply and procurement roadmap for two CCE product categories: Ice-lined (ILR) & Solar Direct Drive (SDD) refrigerators/ freezers.

In 2013, the Gavi Board decided to fund the introduction of inactivated polio vaccine (IPV) in all Gavi-supported countries. This document is the public summary of the supply and procurement roadmap for IPV.

At its November 2013 Board meeting, the Vaccine Alliance opened a funding window for Japanese encephalitis (JE) catch-up campaigns in endemic countries. Download the public summary of the supply and procurement roadmap to learn more about Gavi’s market shaping objectives for the JE vaccine market.

Gavi supports meningococcal vaccines for use in campaigns and routine immunisation in endemic countries in Africa. This document is the public summary of the supply and procurement roadmap for meningococcal vaccine.

In 2008, the Gavi Board approved the strategy to eliminate serogroup A meningococcal meningitis and in 2016, the Gavi Board approved the emergency stockpile commitment to be extended indefinitely. This document is the public summary of the supply and procurement roadmap for meningococcal vaccines for outbreak response.

Gavi’s engagement on measles dates to 2004 and rubella support began in 2011 through the measles-rubella (MR) vaccine. By the end of 2016, Gavi had supported 50 countries with MR programmes. This public summary of the supply and procurement roadmap describes the market, and outlines Gavi’s market shaping ambitions for MR vaccines.

The introduction of hepatitis B and Haemophilus influenzae type b vaccination in all Gavi-supported countries through the five-in-one pentavalent vaccine is one of Gavi’s most significant achievements. This document provides a summary of the supply and procurement roadmap for pentavalent vaccines.

Gavi has supported routine introductions with pneumococcal vaccine since 2009. Find out more about the pneumococcal vaccine market, and Gavi’s approach to shaping it, in the public summary of the vaccine roadmap.

Gavi opened a funding window for typhoid conjugate vaccine in November 2017, supporting catch-up campaigns and co-financing of the vaccine use in routine immunisation programmes. This document is the public summary of the supply and procurement roadmap for TCV.

Gavi has been engaged in yellow fever (YF) vaccination since 2001 in support of WHO efforts to control the disease. This document is the public summary of the supply and procurement roadmap for yellow fever vaccine.

In November 2018, the Gavi Board approved allocation of USD 13.5 million as funding to support a three-year multi-faceted programme to improve yellow fever laboratory capacity in Africa during 2019-2021. This document is the public summary of the supply and procurement roadmap for yellow fever laboratory diagnostics for routine and outbreak yellow fever testing.